Tag:

preventive care

Health

Surishi Pharmaceuticals Introduces Longevity Science to Women’s Healthcare

by Chief Editor
written by Chief Editor

The Longevity Revolution: Women’s Health Takes Center Stage

A paradigm shift is underway in women’s healthcare, moving beyond traditional treatment of symptoms to a proactive focus on cellular health and longevity. Surishi Pharmaceuticals is spearheading this change in India, bringing the emerging science of cellular longevity directly into the conversation around women’s health.

The Invisible Crisis of Cellular Aging in Women

Aging isn’t simply a chronological process; it’s a cascade of cellular changes. For women, this cascade is often steeper and faster than for men, driven by the biological demands of menstruation, pregnancy, postpartum recovery, and perimenopause. These hormonal fluctuations place a sustained burden on mitochondria – the energy-producing engines within cells.

Central to this process is NAD+ (Nicotinamide Adenine Dinucleotide), a coenzyme vital for converting nutrients into energy, repairing DNA, and regulating cellular health. Research indicates that NAD+ levels in women can decline by up to 50% between the ages of 35 and 60. This decline isn’t merely a marker of aging; it actively contributes to fatigue, hormonal disruption, reduced reproductive health, cognitive fog, and increased vulnerability to chronic disease.

NMN: Replenishing Cellular Energy

NMN (Beta-Nicotinamide Mononucleotide) is a naturally occurring molecule and a direct precursor to NAD+. When absorbed, it’s rapidly converted into NAD+ within cells, replenishing reserves depleted by age and stress. Studies from institutions like Harvard Medical School and the University of Washington have established NMN’s role in restoring mitochondrial function, activating sirtuin proteins (associated with DNA repair), supporting metabolic health, reducing inflammation, and supporting reproductive longevity.

NMN: Replenishing Cellular Energy
Surishi Pharmaceuticals Surishi Pharmaceuticals

Surishi Pharmaceuticals’ approach extends beyond NMN, incorporating antioxidants like CoQ10, Astaxanthin, Omega-3 Fatty Acids, Lycopene, Vitamin E, Selenium, and Zinc to provide comprehensive cellular protection.

Connecting Longevity to Common Women’s Health Issues

Surishi Pharmaceuticals draws a direct line between NAD+ depletion and prevalent conditions affecting Indian women, including PCOS and PCOD, infertility, postpartum fatigue, perimenopausal decline, and bone and cardiovascular health. By addressing cellular health at its foundation, the company aims to offer a preventive framework for women’s healthcare.

The Role of the Surishi Academic Council

Every formulation and healthcare initiative at Surishi Pharmaceuticals is guided by the Surishi Academic Council, ensuring research and clinical evidence remain central to their approach. The Council focuses on aligning formulations with the latest global developments in NMN research and educating healthcare professionals about the clinical relevance of NAD+ biology.

From Instagram — related to Surishi, Pharmaceuticals

Bridging the Accessibility Gap in India

Despite the growing recognition of longevity science, preventive healthcare remains largely inaccessible to many Indian women. Surishi Pharmaceuticals is committed to bridging this gap, bringing evidence-based interventions beyond major cities with a national presence and an international office in Munich, Germany.

Future Trends in Women’s Longevity Healthcare

Personalized NAD+ Optimization

As research progresses, expect to witness more personalized approaches to NAD+ optimization. Genetic testing and biomarker analysis will support determine individual NAD+ levels and tailor supplementation strategies for maximum effectiveness.

What Are Sirtuins? The Science Behind Cellular Longevity

Integration with Wearable Technology

Wearable devices will play an increasingly important role in monitoring cellular health metrics, such as energy levels and sleep quality, providing real-time data to inform personalized longevity plans.

Focus on Mitochondrial Health

Mitochondrial dysfunction is a key driver of aging. Future research will likely focus on developing targeted therapies to improve mitochondrial function and protect against oxidative stress.

Expansion of NMN Delivery Methods

Beyond oral supplements, expect to see innovative delivery methods for NMN, such as transdermal patches and liposomal formulations, to enhance absorption and bioavailability.

FAQ

Q: What is NAD+?
A: NAD+ is a coenzyme present in every living cell, responsible for converting nutrients into energy, repairing DNA, and regulating cellular health.

Q: What is NMN?
A: NMN is a naturally occurring molecule and the most direct precursor to NAD+ in the human body.

Q: Why is NAD+ important for women?
A: NAD+ levels decline with age, and this decline is steeper in women due to hormonal demands, contributing to fatigue, hormonal disruption, and increased vulnerability to chronic disease.

Q: What conditions can Surishi Pharmaceuticals address?
A: Surishi Pharmaceuticals focuses on conditions like PCOS and PCOD, infertility, postpartum fatigue, perimenopausal decline, and bone and cardiovascular health.

Q: Where is Surishi Pharmaceuticals located?
A: Surishi Pharmaceuticals is headquartered in New Delhi, India, with an international office in Munich, Germany.

Did you know? Women experience a steeper decline in NAD+ levels than men, making cellular health particularly crucial for their overall well-being.

Pro Tip: Prioritize a diet rich in antioxidants and nutrients that support mitochondrial function to complement any supplementation regimen.

The future of women’s health is proactive, personalized, and focused on cellular longevity. Surishi Pharmaceuticals is at the forefront of this revolution, championing a new era of preventive care for women in India and beyond.

Explore more articles on women’s health and longevity on our website. Subscribe to our newsletter for the latest updates and insights!

0 comments
0 FacebookTwitterPinterestEmail
Health

PAHO Releases Primary Care Guide on Tobacco, Nicotine Cessation

by Chief Editor
written by Chief Editor

The Evolving Landscape of Tobacco & Nicotine Cessation: Beyond the Patch

The Pan American Health Organization’s (PAHO) recent publication of a new clinical booklet for primary healthcare providers signals a critical shift in how we approach tobacco and nicotine dependence. It’s no longer simply about encouraging people to quit smoking; it’s about addressing a complex, evolving addiction landscape shaped by new products, changing behaviors, and a deeper understanding of the underlying factors at play. This isn’t just a regional trend; it’s a global one.

The Rise of Alternative Nicotine Products & the Challenge for Healthcare

While traditional cigarette use is declining in some areas – Mexico, for example, saw a drop from 17.6% in 2016 to 15.1% in 2025 – the surge in e-cigarette and other novel nicotine delivery systems is creating a new wave of dependence. This dual-use phenomenon – individuals smoking cigarettes *and* vaping – is particularly concerning, as it can hinder cessation efforts and potentially expose users to a wider range of health risks. Healthcare providers need to be equipped to address all forms of nicotine addiction, not just cigarettes.

Did you know? Research from the CDC shows that young adults who use e-cigarettes are significantly more likely to start smoking traditional cigarettes later in life.

Personalized Cessation: Moving Beyond “One Size Fits All”

PAHO’s emphasis on patient-centered care is a crucial step forward. The 5As (Ask, Advise, Assess, Assist, Arrange) and 5Rs (Relevance, Risks, Rewards, Roadblocks, Repetition) models provide a framework for tailored interventions. However, truly personalized cessation requires going deeper. Factors like mental health, socioeconomic status, cultural background, and co-occurring substance use disorders all play a significant role in an individual’s ability to quit.

For instance, individuals with mental health conditions are disproportionately affected by tobacco use, with rates often two to three times higher than the general population. Addressing nicotine dependence in these patients requires a collaborative approach involving mental health professionals and a careful consideration of potential interactions between cessation medications and psychiatric treatments.

The Role of Technology: AI, Telehealth, and Digital Therapeutics

The integration of technology is poised to revolutionize tobacco and nicotine cessation. Mexico’s implementation of AI-powered chest X-ray analysis for early lung cancer detection is a prime example of how technology can support preventative care. But the potential extends far beyond diagnostics.

Telehealth platforms can provide remote counseling and support, increasing access to cessation services for individuals in rural or underserved areas. Digital therapeutics – evidence-based behavioral interventions delivered via smartphone apps or online platforms – offer personalized support, tracking, and motivational tools. These tools can be particularly effective for young adults who are comfortable using technology.

Pharmacotherapy: New Options and Personalized Approaches

While nicotine replacement therapy (NRT) remains a cornerstone of cessation treatment, research is exploring new pharmacotherapeutic options. Studies are investigating the potential of medications that target nicotine receptors in the brain, offering alternative pathways to reduce cravings and withdrawal symptoms.

Pro Tip: Genetic testing may one day play a role in determining which cessation medications are most likely to be effective for a given individual, based on their unique metabolic profile.

Policy & Prevention: A Multi-Pronged Approach

PAHO’s work complements broader public health efforts, such as Mexico’s recent increase in excise taxes on tobacco products. Taxation, combined with comprehensive smoke-free policies, public awareness campaigns, and restrictions on advertising, creates a supportive environment for cessation. However, policies must be continually updated to address the emergence of new nicotine products and marketing tactics.

Looking Ahead: Predictive Analytics and Proactive Intervention

The future of tobacco and nicotine cessation will likely involve a more proactive, data-driven approach. Predictive analytics, using machine learning algorithms, could identify individuals at high risk of initiating nicotine use or relapsing after quitting. This would allow healthcare providers to target interventions more effectively, offering preventative counseling and support before addiction takes hold.

FAQ

Q: Is vaping as harmful as smoking cigarettes?
A: While the long-term health effects of vaping are still being studied, e-cigarettes are not harmless. They contain nicotine, which is addictive, and other potentially harmful chemicals.

Q: What is the 5As model for tobacco cessation?
A: The 5As stand for Ask (about tobacco use), Advise (to quit), Assess (readiness to quit), Assist (with cessation), and Arrange (follow-up support).

Q: Are there any new medications for nicotine addiction?
A: Research is ongoing, but several medications are being investigated that target nicotine receptors in the brain, offering potential alternatives to traditional NRT.

Q: How can I find help to quit smoking or vaping?
A: Talk to your doctor, visit the PAHO website (https://www.paho.org/en), or explore resources from the CDC (https://www.cdc.gov/tobacco/quit_smoking/index.htm).

What are your experiences with tobacco or nicotine cessation? Share your thoughts in the comments below, and explore our other articles on health and wellness for more insights.

0 comments
0 FacebookTwitterPinterestEmail
Health

SCOTUS will hear case threatening no-cost preventive care

by Chief Editor
written by Chief Editor

The Future of Preventive Care: A Deep Dive into the ACA Case

The upcoming U.S. Supreme Court case, Braidwood v. Kennedy, has sparked widespread attention for its potential to reshape preventive healthcare in America. This case questions the constitutionality of the Affordable Care Act’s (ACA) mandate that insurers cover preventive services at no cost to patients. With a ruling expected this April, the implications could be far-reaching for millions of Americans.

Understanding the Stakes

If the ACA’s mandate is struck down, millions could face costs for preventive services or may avoid these services altogether. Low-income individuals and minority communities, who already experience significant barriers to healthcare, could be disproportionately affected. The Center for Value Based Insurance Design at the University of Michigan predicts a decline in overall health outcomes and a rise in racial disparities if these services require out-of-pocket spending.

The Legal Quandary

The case pivots on the legal standing of the U.S. Preventive Services Task Force (USPSTF) members — are they appointed in violation of the Constitution? The Department of Justice defends that these members are “inferior officers” and that the Secretary of HHS holds the power to make final decisions. Such nuances could have a significant impact on how preventive services are validated and offered.

The Ripple Effects

Section 2713 of the ACA, challenged by Braidwood Management, ensures coverage for services like contraceptive care, cancer screenings, and immunizations. If deemed unconstitutional, not only would coverage of these services be jeopardized, but the trust in policies designed to protect health for all could be undermined.

Real-Life Impacts and Examples

Examples abound of services already benefiting from the ACA mandate. The Prevntive Services Task Force updated its recommendations for osteoporosis and cancer screenings, directly benefiting millions. Women now have the option for more frequent screenings starting at earlier ages, aligning with personal and preventive needs.

Looking Ahead: Projections and Predictions

Experts, such as V-BID Center Director A. Mark Fendrick, stress that although removing the mandate might not save employers huge sums, it could discourage the provision of no-cost preventive care. The Employee Benefit Research Institute’s analysis echoes this, suggesting minimal employer savings against a backdrop of vital sustained healthcare coverage.

FAQs on the ACA Preventive Care Case

  • What services are at risk if Section 2713 is struck down? Preventive services like cancer screenings, immunizations, and certain health counseling may no longer be covered without cost-sharing.
  • Who is most at risk if the mandate is overturned? Low-income individuals, minority groups, and others with existing healthcare access barriers.
  • Why is the appointment of USPSTF members under scrutiny? The constitutional discussion centers on whether they have been validly appointed as “inferior officers” or not.

Call to Action

This case is not just a legal battle but a crucial health issue affecting lives and access to care. As we approach the ruling, let’s raise awareness and advocate for equitable healthcare. Share this article, comment with your thoughts, and explore more resources on our site.

Engage Further

Did you know? The ACA mandate affects more than 232 million Americans with private health insurance who benefit from no-cost preventive services. As we navigate these changes, your engagement is crucial.

0 comments
0 FacebookTwitterPinterestEmail